Performance Measurement Network

Question: Dabigatran (PRADAXA) use in Stroke Patients

Can we currently answer yes to VTE prophylaxis and antithrombotic therapy by end of hospital day 2 and discherged on antithrombotic and anticoagulation therapy if Pradaxa is administerd by hosptial day 2 and at discharge? If no, will this be changing and when?

Answer:

PRADAXA (dabigatron)is being added to Appendix C, Table 8.2 Antithrombotic Nedications-Stroke and Table 8.3 Anticoagulant Medications-Stroke with the next version of the manual (Version 3.4, applicable to discharges Jan.1 through June 30, 2012). This change will address measures STK-2, STK-3, STK-5.

In addition, we are adding a bullet(Notes for Abstraction), instructing the abstractor to select 'Yes' for "Reason for No VTE Prophylaxis-Hospital Admission",if the patient is receiving anticoagulation therapy for stroke prevention(PRADAXA)the day of or after hospital admission. The note will be the same as we currently have for patients receiving continuous IV heparin. This change will address STK-1.

PRADAXA is not approved for 'VTE prophylaxis'; therefore, it will not be added as an allowable value to the definition for VTE Prophylaxis. The approved indication is "stroke prevention in patients with atrial fibrillation".

Question Details
Focus area(s): Chart Abstracted Measure Specifications – Clinical
Related documents: STK, STK- 1,2,3
File:

Copyright © by the contributing authors. All material on this collaboration platform is the property of the contributing authors.
Ideas, requests, problems regarding Performance Measurement Network? Send feedback